MacuLogix Announces Optometric Advisory Board

Seven industry leaders to provide strategic input on the AdaptDx and practical guidelines for AMD

MIDDLETOWN, PA, August 7, 2017– MacuLogix, Inc., the only company to equip eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), announces its new Optometric Advisory Board. These seven Clinical Advisors were appointed to provide strategic input on key initiatives and serve as company ambassadors at industry events and in the media.

The Optometric Advisory Board, which is led by MacuLogix Co-Founder and Chief Technology Officer Greg Jackson, PhD, is currently tasked with documenting standard of care guidelines for the treatment of AMD. The final consensus paper, which is scheduled to publish this fall, will clearly and succinctly outline essential, practical steps that optometrists can reference in every-day clinical practice. 

The MacuLogix Optometric Clinical Advisors are:

• Glenn S. Corbin, OD – Wyomissing Optometric Center in Wyomissing, PA

• Steven G. Ferrucci, OD, FAAO – Sepulveda VA Hospital in Sepulveda, CA

• Jeffry D. Gerson, OD, FAAO – Grin Eye Care in Olathe, KS

• Paul M. Karpecki, OD, FAAO – Kentucky Eye Institute in Lexington, KY

• Gary S. Kirman, OD – Kirman Eye in Hummelstown, PA

• Pamela Lowe, OD, FAAO – Professional Eye Care Center in Niles, IL

• Laurie Sorrenson, OD, FAAO – Lakeline Vision Source in Cedar Park, TX

“We are very excited to partner with these industry leaders and AdaptDx super-users to help us achieve our vision of eliminating blindness caused by age-related macular degeneration,” said William McPhee, President and CEO of MacuLogix. “Each Advisor is an early adopter of technology and their collective experiences are helping us drive greater adoption of the AdaptDx.”

“With the AdaptDx, MacuLogix is changing the way we detect and monitor AMD. So much so, that I’m confident this device will have a major impact on reducing blindness caused by this chronic disease,” said Clinical Advisor Jeffry Gerson, OD, FAAO. “I couldn’t be more excited to work with my esteemed colleagues and the MacuLogix team to affect real change in our industry.”

To learn more about each Clinical Advisor, visit our team.

About MacuLogix

MacuLogix, Inc. equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx, MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Through its AdaptDx dark adaptation biomarker, MacuLogix enables eye care professionals to detect, monitor and treat AMD three years before it can be seen clinically. MacuLogix provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx.